THERAPY DOSSIER · th-ad01fe1955c8

C20, a specific pharmacological PKCtheta inhibitor (genetic arm used PKCtheta knockout mice)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Crush
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32244482 ↗2020Reported benefit

Targeting PKCtheta Promotes Satellite Cell Self-Renewal.

MouseCrushLimb / muscle crushPKCtheta knockout on C57BL/6J background with C57BL/6J wild-type controlsn = Reported as means of at least three experiments; per-group…Intraperitoneal in vivo; culture medium in vitro5 mg/kg in vivo; 0.5, 1 and 2 micromolar in vitroStarted 1 day before cardiotoxin injection

Model: Acute cardiotoxin injury: 20 microlitres of Naja pallida cardiotoxin given as two 10 microlitre injections into the gastrocnemius; a repeated injury protocol used three cardiotoxin injuries 20 days apart

Loss or pharmacological inhibition of PKCtheta increased symmetric self-renewing divisions via increased symmetric Pard3 distribution, expanding the quiescent satellite cell pool 28 days after cardiotoxin injury by 64.4 percent in knockout mice and about 50 percent with C20, and by 110 percent in k…

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…